Autologous bone marrow mononuclear cell transplantation
Phase 1Withdrawn 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cerebrovascular Accident
Conditions
Cerebrovascular Accident
Trial Timeline
Dec 1, 2008 → Jan 1, 2014
NCT ID
NCT02065778About Autologous bone marrow mononuclear cell transplantation
Autologous bone marrow mononuclear cell transplantation is a phase 1 stage product being developed by Brain Biotech for Cerebrovascular Accident. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02065778. Target conditions include Cerebrovascular Accident.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02009124 | Phase 2 | Withdrawn |
| NCT02028104 | Phase 1 | Withdrawn |
| NCT02027246 | Phase 1 | Withdrawn |
| NCT02050776 | Phase 1 | Withdrawn |
| NCT02065778 | Phase 1 | Withdrawn |
Competing Products
14 competing products in Cerebrovascular Accident
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM872 (zonampanel) | Astellas Pharma | Phase 2 | 52 |
| donepezil hcl | Eisai | Phase 3 | 77 |
| Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride | Eisai | Approved | 85 |
| ONO-2506 | Ono Pharmaceutical | Phase 2/3 | 65 |
| Abciximab | Eli Lilly | Phase 3 | 77 |
| atomoxetine + Stimulants | Eli Lilly | Pre-clinical | 23 |
| ticagrelor + ASA + Placebo+ASA | AstraZeneca | Approved | 85 |
| Valsartan | Novartis | Pre-clinical | 23 |
| Atorvastatin | Pfizer | Approved | 84 |
| Rivaroxaban | Bayer | Pre-clinical | 20 |
| Darolutamide (BAY1841788) + Enzalutamide | Bayer | Phase 1 | 30 |
| Botulinum toxin type A + Placebo | Ipsen | Approved | 82 |
| Atorvastatin 20mg | Brain Biotech | Approved | 77 |
| Roflumilast Oral Tablet | Brain Biotech | Phase 2 | 44 |